Earn points on every order New products in stock Free 51-page beginner’s guide
← Back to Compound Library

ADIPOTIDE (FTPP)

An experimental “fat-targeted” peptide that tries to kill the blood vessels feeding fat tissue, causing fat cells to die off. It caused dramatic weight loss in monkeys, but also kidney damage. Human safety is unproven. This is the riskiest entry in this section.

Research referenceCommunity compiled

Molecular profile

The molecule itself: sequence, composition, mass, target, and registry identifiers.

Molecular formula
C₁₁₁H₂₀₆N₃₆O₂₈S₂
Average mass
2557.2 Da
CAS number
859216-15-2
Registry
PubChem CID 163360068
Formula, mass and identifiers from PubChem CID 163360068.
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

Adipotide (Prohibitin-Targeting Peptide / FTPP) is an experimental peptidomimetic designed to target and eliminate white adipose tissue by starving its blood supply.

What problem it targets: It was created to treat morbid obesity and severe metabolic dysfunction by directly shrinking visceral and subcutaneous fat depots that resist diet and exercise.

What It Does

• Homes in on fat-tissue blood vessels: The targeting domain binds specifically to prohibitin, a protein uniquely expressed on the endothelial surface of white fat capillaries.

• Triggers targeted blood vessel destruction: Its apoptotic domain disrupts mitochondrial membranes in those vessel cells, cutting off oxygen and nutrients to neighboring fat cells.

• Rapidly reduces white fat volume: Starved fat cells undergo programmed cell death and are reabsorbed and cleared by the body, resulting in marked weight reduction in animal studies.

• Realistic expectations: While extraordinarily potent at eliminating fat in primate trials, it exhibits significant, dose-dependent renal stress and kidney toxicity that have restricted human viability.

Reconstitution

Vial sizeBAC water / SolventConcentrationNote
2 mg+ 0.4 mL5 mg/mLNo validated human dose, figures are research-derived only
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL

Protocol

Handling & Stacking

Injection site
SubQ if used (studies used IV). Rotate.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted: 36–46°F, best used within ~2–3 weeks (structure-based estimate); potency fades before the 28-day sterility limit, so keep it cold, dark, and use it sooner.
Side effects
Renal toxicity (primate data), dehydration, electrolyte disturbance. Human side-effect profile unknown.
What to expect
  • Unknown in humans.
  • Animal data showed rapid fat loss but with kidney injury, the risk/benefit is not established.
  • Supply math Not applicable, no validated human dosing.
  • Research compound only.
Pairs well with
Not recommended for stacking given the safety uncertainty
Avoid
Any pre-existing kidney disease. Dehydration. Pregnancy. Concurrent nephrotoxic drugs. Honestly: avoid pending human safety data
Approved drug
Approved weight-loss drugs are far better proven: semaglutide (Wegovy), tirzepatide (Zepbound), orforglipron (Foundayo, oral, 2026), plus phentermine, Qsymia, Contrave and orlistat.

Safety & Patient Education

Contraindications
Any kidney disease or reduced renal function Dehydration or conditions causing volume depletion Pregnancy and lactation Concurrent nephrotoxic agents (NSAIDs, certain antibiotics, contrast)
Warnings
Dose-dependent renal toxicity in primate studies, the central safety concern No human safety, efficacy, or dosing data Proapoptotic mechanism is non-selective enough to warrant serious caution Not an approved drug anywhere
Drug interactions
Other nephrotoxic drugs: compounded kidney risk, avoid Diuretics / dehydration: worsen renal stress
Labs
  • Renal function (creatinine, eGFR, urinalysis) before, during, and after; mandatory if used at all Electrolytes and hydration status Out of range?
  • Any creatinine rise or eGFR drop = kidney injury starting → stop immediately (this is the defining risk).
Stop criteria
Any rise in creatinine or fall in eGFR Reduced urine output, flank pain, or edema Any sign of systemic illness
Patient education
This is the highest-risk compound in this section, included for completeness, not endorsement The proven harm in animals was kidney injury; human safety is unknown Safer, proven fat-loss tools (GLP-1s, AOD-9604) exist; prefer them If considered at all, only under medical supervision with renal monitoring
References
PubMed · clinicaltrials.gov · researchdosing